U.S. scientists have used LIBRA-seq technology to speed up the search for antibodies that can
“This is one of the ways to proactively create"The repertoire of potential therapeutics against future outbreaks," explains Ivelin Georgiev, Ph.D., director of Vanderbilt's Computational Microbiology and Immunology Program, "Pathogens continue to evolve, and we're basically playing catch-up."
In his report for the magazineCell Reports scientists describe how monoclonalantibodies in a patient who has recovered from COVID-19. They are reported to be "showing powerful neutralization" against SARS-CoV-2. The antibodies are also effective against new variants of the coronavirus that are slowing the fight against the pandemic, biologists said.
New antibodies are unusualgenetic and structural characteristics that distinguish it from other monoclonal antibodies commonly used to treat COVID-19. It is believed that SARS-CoV-2 is less likely to mutate to avoid an antibody it has not "seen" before.
LIBRA-seq stands for B cell bindingreceptor with antigen specificity through sequencing. Method developed in 2019 by Ian Setliffe, Ph.D., a former graduate student in Georgiev's lab who now works in the biotech industry, and Andrea Shiakolas, a current graduate student at Vanderbilt.
Read more
An airplane with articulated wings and a tail appeared. It can take off without a run
Тепловой парадокс наноматериалов решен. Охладить технику можно в 3 раза эффективнее
An ordinary plane will be turned into a flying laboratory "Excalibur" for fighters
Monoclonal antibodies - antibodies,produced by immune cells belonging to the same cell clone, that is, derived from one plasma progenitor cell (as opposed to polyclonal antibodies).